Ranolazine extended-release

Drug Profile

Ranolazine extended-release

Alternative Names: CVT 303; CVT 3041; KEG 1295; RAN D; Ran4; Ranexa; Ranolazine hydrochloride; RS 43285; RS 43285-003; RS 43285-193

Latest Information Update: 13 Apr 2017

Price : $50

At a glance

  • Originator Syntex Pharmaceuticals International
  • Developer CV Therapeutics; Gilead Sciences; Kissei Pharmaceutical; Menarini; North Shore-Long Island Jewish Health System; University of Rochester
  • Class Acetanilides; Anti-ischaemics; Ischaemic heart disorder therapies; Piperazines; Small molecules
  • Mechanism of Action Partial fatty acid oxidation inhibitors; Pyruvate dehydrogenase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Angina pectoris
  • Phase III Acute coronary syndromes; Atrial fibrillation; Type 2 diabetes mellitus
  • Phase II Aortic valve stenosis; Heart failure; Left ventricular hypertrophy; Long QT syndrome; Myocardial ischaemia
  • Discontinued Intermittent claudication; Ventricular arrhythmias

Most Recent Events

  • 05 Apr 2017 Cardiovascular Institute of the South Clinical Research Corporation and Gilead Sciences terminate the phase II ERIC trial in Cardiomyopathy due to lack of resources (NCT01705509)
  • 27 Mar 2017 North Florida Foundation for Research and Education and Gilead terminates a phase II trial for Angina pectoris in USA (PO) (NCT02147834)
  • 27 Feb 2017 Gilead Sciences has patent protection for ranolazine extended-release in USA and European Union (Gilead Sciences 10-k, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top